A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

  • End date
    Nov 30, 2023
  • participants needed
  • sponsor
    Sumitomo Dainippon Pharma Oncology, Inc
Updated on 31 July 2021
tumor treating fields therapy


This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.

Condition Glioblastoma Multiforme, glioblastoma
Treatment bevacizumab, DSP-7888 Dosing Emulsion
Clinical Study IdentifierNCT03149003
SponsorSumitomo Dainippon Pharma Oncology, Inc
Last Modified on31 July 2021


Yes No Not Sure

Inclusion Criteria

Patients or their legal representatives must be able to provide written informed consent
Histologically confirmed diagnosis of supratentorial GBM (Grade 4 astrocytoma)
Radiographic evidence of first recurrence or progression of GBM following primary therapy consisting of surgery (biopsy or resection) and chemoradiation; patients may have undergone a second debulking surgery following initial recurrence or progression. Patients whose tumors are O6 methyl guanyl-methyltransferase (MGMT) methylated-promoter negative need not have received chemotherapy in the past to be eligible
Human leukocyte antigen type HLA-A _02:01, HLA-A_ 02:06, or HLA-A24:02
Age 18
KPS score of 60
Serum creatinine value <2X the upper limit of normal (ULN) for the reference laboratory
Alanine aminotransferase/aspartate aminotransferase <3X the ULN and total bilirubin <2 the ULN for the reference laboratory
Men and women of childbearing potential must agree to use a reliable method of contraception (oral contraceptives, implantable hormonal contraceptives, or double barrier method) or agree to completely refrain from heterosexual intercourse for the duration of the study and for 180 days following the last dose of DSP-7888 Dosing Emulsion
Patients must have recovered from the effect of all prior therapy to Grade 2 or less
Patients must be at least 28 days from any major surgery, and any surgery incisions or wounds must be completely healed
Patients must be at least 12 weeks from the completion of prior radiation therapy (RT) in order to discriminate pseudo progression of disease from progression
Patients must be at least 4 weeks from the completion of prior systemic or intracranial chemotherapy
Patients must stop Novo-TTF treatment one day prior to study therapy (no washout period is needed). However, any wounds from TTF must be adequately healed per Inclusion Criterion #11.15. For patients who are not receiving therapeutic anticoagulation treatment, an international normalized ratio (INR) and a PTT 1.5 the ULN; patients who are receiving anticoagulation treatment should be on a stable dose
Patient's left ventricular ejection fraction (LVEF) > 40%. 17. Patient has a resting pulse oximetry of 90% or higher

Exclusion Criteria

Patients with any of the following will be excluded from the study
Prior therapy with Bev
Patients with secondary GBM
Any anti-neoplastic therapy, including RT, for first relapse or recurrence
Evidence of leptomeningeal spread of tumor or any history, presence, or suspicion of metastatic disease extracranially
Evidence of impending herniation on imaging
Has known multifocal disease. Multifocal disease is defined as discrete sites of disease without contiguous T2/FLAIR abnormality that require distinct radiotherapy ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR abnormality as the main lesion(s) and that are encompassed within the same radiotherapy port as the main lesion(s) are permitted
Patients with infections that have required treatment with systemic antibiotics within 7 days of first dose of protocol therapy
The need for systemic glucocorticoids in doses in excess of 4 mg/day of dexamethasone or in comparable doses with other glucocorticoids
Treatment with any investigational agents within 5 half-lives of the agent in question or, if the half-life is unknown, within 28 days of enrollment
Pregnant or lactating females
Prior history of malignancy within 3 years of enrollment other than basal or squamous cell carcinoma of the skin, cervical intra-epithelial neoplasia, in situ carcinoma of the breast, or prostate cancer treated with surgery or RT with a prostate specific antigen of <0.01 ng/mL
Patients with active autoimmune diseases within 2 years of enrollment into the study including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, Wegener's granulomatosis, ulcerative colitis, Crohn's disease, myasthenia gravis, Graves' disease, or uveitis except for psoriasis not requiring systemic therapy, vitiligo or alopecia areata, or hypothyroidism; if an autoimmune condition has been clinically silent for 12 months or greater, the patient may be eligible for enrollment
Patients on immunosuppressive therapies; the use of topical, inhalational, ophthalmologic or intra articular glucocorticoids, or the use of physiologic replacement doses of glucocorticoids are permitted
Patients with primary immunodeficiency diseases
Patients with significant bleeding in the preceding 6 months or with known coagulopathies
History of abdominal fistula, intestinal perforation, or intra-abdominal abscess in the preceding 12 months
Positive serology for human immunodeficiency virus (HIV) infection, active hepatitis B, or untreated hepatitis C; patients who have completed a course of anti-viral treatment for hepatitis C are eligible
In cases of negative results for HepB surface antigen with positive HepB core antibody, HBV DNA testing is required
Patient has a medical history of frequent ventricular ectopy, e.g., non-sustained ventricular tachycardia (VT)
Significant cardiovascular disease, including New York Hospital Association Class III or IV congestive heart failure, myocardial infarction within 6 months of enrollment, unstable angina, poorly controlled cardiac arrhythmias, or stroke within the preceding 6 months
Any other uncontrolled inter current medical condition, including systemic fungal, bacterial, or viral infection; uncontrolled hypertension; diabetes mellitus; or chronic obstructive pulmonary disease requiring 2 or more hospitalizations in the preceding 12 months
Any psychiatric condition, substance abuse disorder, or social situation that would interfere with a patient's cooperation with the requirements of the study
Known sensitivity to Bev or any of the components of DSP-7888 Dosing Emulsion
Patient has a QTcF (QT corrected based on Fridericia's equation) interval > 480 msec (CTCAE = Grade 2) or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at screening. (Patients with bundle branch block and a prolonged QTc interval should be reviewed by the Medical Monitor for potential inclusion.)
Patient has dyspnea at rest (CTCAE Grade 3) or has required supplemental oxygen within 2 weeks of study enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note